Williams-Beuren syndrome is a rare multisystem neurodevelopmental disorder caused by a 1.55-1.84-Mb hemizygous deletion on chromosome 7q11.23. The classical phenotype consists of characteristic facial features, supravalvular aortic stenosis, intellectual disability, overfriendliness, and visuospatial impairment. So far, 26-28 genes have been shown to contribute to the multisystem phenotype associated with Williams-Beuren syndrome. Among them, haploinsufficiency of the ELN gene has been shown to cause the cardiovascular anomalies. Identification of patients with atypical deletions has provided valuable information for genotype-phenotype correlation, in which other genes such as LIMK1,CLIP2, GTF2IRD1, or GTF2I have been correlated with specific cognitive profiles or craniofacial features. Here, we report the clinical and molecular characteristics of a patient with an atypical deletion that does not include the GTF2I gene and only partially includes the GTF2IRD1 gene.

Keywords:
Deletion 7q11.23, Genomic disorders, GTF2I, GTF2IRD1, Segmental duplications, Williams-Beuren syndrome, Williams syndrome
1.
Antonell A, Del Campo M, Magano LF, Kaufmann L, de la Iglesia JM, et al: Partial 7q11.23 deletions further implicate GTF2I and GTF2IRD1 as the main genes responsible for the Williams-Beuren syndrome neurocognitive profile. J Med Genet 47:312-320 (2010).
2.
Ball RS: The Gesell developmental schedules. J Abn Child Psychol 5:233-239 (1977).
3.
Dai L, Bellugi U, Chen XN, Pulst-Korenberg AM, Järvinen-Pasley A, et al: Is it Williams syndrome? GTF2IRD1 implicated in visual-spatial construction and GTF2I in sociability revealed by high resolution arrays. Am J Med Genet Part A 149A:302-314 (2009).
4.
Enkhmandakh B, Makeyev AV, Erdenechimeg L, Ruddle FH, Chimge NO, et al: Essential functions of the Williams-Beuren syndrome-associated TFII-I genes in embryonic development. Proc Natl Acad Sci USA 106:181-186 (2009).
5.
Ferrero GB, Howald C, Micale L, Biamino E, Augello B, et al: An atypical 7q11.23 deletion in a normal IQ Williams syndrome patient. Eur J Hum Genet 18:33-38 (2010).
6.
Gagliardi C, Bonaglia MC, Selicorni A, Borgatti R, Giorda R: Unusual cognitive and behavioural profile in a Williams syndrome patient with atypical 7q11.23 deletion. J Med Genet 40:526-530 (2003).
7.
Hirota H, Matsuoka R, Chen XN, Salandanan LS, Lincoln A, et al: Williams syndrome deficits in visual spatial processing linked to GTF2IRD1 and GTF2I on chromosome 7q11.23. Genet Med 5:311-321 (2003).
8.
Howald C, Merla G, Digilio MC, Amenta S, Lyle R, et al: Two high throughput technologies to detect segmental aneuploidies identify new Williams-Beuren syndrome patients with atypical deletions. J Med Genet 43:266-273 (2006).
9.
Howard ML, Palmer SJ, Taylor KM, Arthurson GJ, Spitzer MW, et al: Mutation of Gtf2ird1 from the Williams-Beuren syndrome critical region results in facial dysplasia, motor dysfunction, and altered vocalisations. Neurobiol Dis 45:913-922 (2012).
10.
Merla G, Howald C, Henrichsen CN, Lyle R, Wyss C, et al: Submicroscopic deletion in patients with Williams-Beuren syndrome influences expression levels of the nonhemizygous flanking genes. Am J Hum Genet 79:332-341 (2006).
11.
Morris CA: Introduction: Williams syndrome. Am J Med Genet Part C Semin Med Genet 154C:203-208 (2010).
12.
Morris CA, Demsey SA, Leonard CO, Dilts C, Blackburn BL: Natural history of Williams syndrome: physical characteristics. J Pediatr 113:318-326 (1988).
13.
Schneider T, Skitt Z, Liu Y, Deacon RM, Flint J, et al: Anxious, hypoactive phenotype combined with motor deficits in Gtf2ird1 null mouse model relevant to Williams syndrome. Behav Brain Res 233:458-473 (2012).
14.
Tassabehji M, Hammond P, Karmiloff-Smith A, Thompson P, Thorgeirsson SS, et al: GTF2IRD1 in craniofacial development of humans and mice. Science 310:1184-1187 (2005).
15.
Vandeweyer G, Van der Aa N, Reyniers E, Kooy RF: The contribution of CLIP2 haploinsufficiency to the clinical manifestations of the Williams-Beuren syndrome. Am J Hum Genet 90:1071-1078 (2012).
16.
Young EJ, Lipina T, Tam E, Mandel A, Clapcote SJ, et al: Reduced fear and aggression and altered serotonin metabolism in Gtf2ird1-targeted mice. Genes Brain Behav 7:224-234 (2008).
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.